Clinical Trials on B-Cell Malignancies in China

Total 5374 results

Shanghai Tongji Hospital, Tongji University School...

Recruiting

Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.

B Cell Malignancies

China
TransThera Sciences (Nanjing), Inc.

Recruiting

A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

B-Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/22 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/79b Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/70 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shanghai Escugen Biotechnology Co., Ltd

Recruiting

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

China
Minghui Pharmaceutical (Shanghai) LTD

Recruiting

This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies

China
BeiGene

Active, not recruiting

Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies

Mature B-cell Malignancies

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Not yet recruiting

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

CD19-positive Relapsed or Refractory B-cell Malignancies

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

4SCAR19U T Cells Targeting B Cell Malignancies

B Cell Malignancies

China
Haisco Pharmaceutical Group Co., Ltd.

Recruiting

A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-Cell Malignancies

China, Australia
BeiGene

Recruiting

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

B-cell Malignancies

China, Italy, United States, Spain, United Kingdom, Poland, Czechia, Netherlands, Greece, France, Sweden, Korea, Republic of, Turkey
Affiliated Hospital to Academy of Military Medical...
Beijing JD Biotech Co. LTD.

Recruiting

CAR-NK Targeted CD19 for r/r B-cell Malignancies

Adult Relapsed/Refractory B-cell Hematologic Malignancies

China
AstraZeneca

Active, not recruiting

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

Part1: Advanced B-cell Malignancies | Part2: r/rCLL and r/rMCL | Part3: Untreated CLL

Japan
920th Hospital of Joint Logistics Support Force...
Nanjing Bioheng Biotech Co., Ltd.

Withdrawn

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

B-cell Lymphoma

China
Sunshine Lake Pharma Co., Ltd.

Active, not recruiting

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

Relapsed or Refractory B-cell Hematologic Malignancies

China
Kunming Hope of Health Hospital

Withdrawn

Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies

B-cell Lymphoma | B-cell Leukemia

China
Shenzhen Geno-Immune Medical Institute

Unknown

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

B-cell Malignancies

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Lymphoma Recurrent

China
Xuzhou Medical University

Recruiting

Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

China
Shenzhen Geno-Immune Medical Institute

Unknown

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

B-cell Malignancies

China
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | B-Cell Non-Hodgkin Lymphomas(NHL)

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

Relmacabtagene Autoleucel in Hematologic Malignancies

Lymphoma, B-Cell | Follicular Lymphoma | Large B-cell Lymphoma

China
Wuhan Union Hospital, China
Chengdu USino Technology Biology Co., Ltd

Recruiting

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphoblastic Leukemia

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

4SCAR-T Therapy Post CD19-targeted Immunotherapy

CD19 Negative B-cell Malignancies

China
Xinqiao Hospital of Chongqing
The First Affiliated Hospital of Anhui Medical University; Nanfang Hospital... and other collaborators

Unknown

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
920th Hospital of Joint Logistics Support Force...

Recruiting

A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies

B-Cell Lymphoblastic Leukemia/Lymphoma

China
Kai Lin Xu; Jun Nian Zheng
iCarTAB BioMed Inc.

Unknown

CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

Recurrent or Refractory B Cell Malignancy

China
Merck Sharp & Dohme LLC

Active, not recruiting

A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)

Mature B-cell Neoplasms

Japan
Innovative Cellular Therapeutics Co., Ltd.

Unknown

Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

Lymphoma, B-Cell | Leukemia, B-Cell

China
Timmune Biotech Inc.
Hunan Provincial People's Hospital

Unknown

Treatment of Hematological Malignancy With Novel CAR-T Cells.

Multiple Myeloma | B-cell Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma

China
MingSight Pharmaceuticals, Inc
Shenzhen MingSight Relin Pharmaceutical Co., Ltd

Recruiting

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Relapsed or Refractory B-cell Lymphoma | Marginal Zone Lymphoma (MZL)

China
Nanfang Hospital of Southern Medical University

Recruiting

Induced-T Cell Like NK Cells for B Cell Malignancies

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | B Cell Leukemia | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

CD19+ Lymphoma, B-Cell | CD19+ Leukemia, B-Cell

China
Institute of Hematology & Blood Diseases Hospital
Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd.

Unknown

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Transformed Lymphoma

China
Qian Wenbin

Not yet recruiting

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

China
Chinese PLA General Hospital

Unknown

A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

B Cell Lymphoma | B Cell Leukemia

China
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma

B Cell Lymphoma | B Cell Leukemia

China
Shandong Provincial Hospital

Recruiting

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

China
AstraZeneca

Active, not recruiting

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Phase I: Relapsed or Refractory B-cell Malignancies | Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia

China
BeiGene

Active, not recruiting

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Mature B-cell Malignancies

Japan
Beijing Yongtai Ruike Biotechnology Company Ltd

Recruiting

Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

China
RenJi Hospital

Recruiting

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
Immune Cell, Inc.
Weifang People's Hospital

Recruiting

A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia

B Cell Lymphoma | B Cell Leukemia

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
The Second Hospital of Hebei Medical University

Unknown

CAR T Cells for Refractory B Cell Malignancy

B-Cell Leukemia | B-Cell Lymphoma

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Lymphoma, Non-Hodgkin | Diffuse Large B Cell Lymphoma

China
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China

Clinical Trials on B-Cell Malignancies in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations